VRM
IMMU

Vectors Research Management’s Immunomedics Inc IMMU Stock Holding History

Vectors Research Management’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,000
Closed -$42K – 582
2019
Q4 		$42K Hold
2,000
– – 0.02% 197
2019
Q3 		$27K Hold
2,000
– – 0.01% 205
2019
Q2 		$28K Hold
2,000
– – 0.02% 197
2019
Q1 		$38K Buy
+2,000
New +$32.2K 0.02% 182

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vectors Research Management's IMMU Position: Q1 2020 in Review

Vectors Research Management sold out of Immunomedics Inc (IMMU) in Q1 2020, closing a stake of 2,000 shares — an estimated $42K sold.

Vectors Research Management first reported a position in IMMU in Q1 2019 and held it in 4 quarters. The position peaked at $42K in Q4 2019. 220 funds tracked by Wall St. Rank hold IMMU as of Q1 2020.

  • Vectors Research Management reported no remaining Immunomedics Inc position as of Q1 2020 after selling out during the quarter.
  • Vectors Research Management sold 2,000 Immunomedics Inc shares in Q1 2020, an estimated $42K.
  • Vectors Research Management first reported a position in Immunomedics Inc in Q1 2019 and held it in 4 quarters.
  • Vectors Research Management's Immunomedics Inc position peaked at $42K in Q4 2019.
  • 220 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2020.

Based on Vectors Research Management's 13F filing for Q1 2020, filed 14 May 2020.